<DOC>
	<DOCNO>NCT00423384</DOCNO>
	<brief_summary>Loss bone mass common complication patient end-stage-renal failure , particularly transplantation . In addition standard underlie therapy calcium active vitamin D , study effect ibandronate ( bisphosphonate ) versus placebo bone mineral density well incidence fracture rate kidney transplantation.We also wish study whether prevented bone loss also lead reduce cardiovascular disease . Patients follow 12 month transplantation , ibandronate treatment one injection every 3 month .</brief_summary>
	<brief_title>Ibandronate Versus Placebo Prevention Bone Loss After Renal Transplantation .</brief_title>
	<detailed_description>Demographic , medical history , previous current medication , well baseline measurement Bone Mineral Density ( BMD ) , laboratory efficacy safety variable well Quality-of-Life score undertaken period 1 week prior transplantation 1 week transplantation . In period , exist fracture determine use traditional x-ray thoraco-lumbar columna . Renal graft function well transplantation complication follow tightly , calcium supplementation well active vitamin D ( calcitriol ) administer together standard immunosuppressive regimen . As soon patient recovered transplantation , renal functioning consider sufficiently stable , later 28 day transplantation , qualify patient randomise receive either ibandronate placebo , stratify gender . Bone mineral density clinical data laboratory test follow 12 month transplantation describe attached flowchart ( section 11.1 ) , hospital visit administration study drug follow-up 13 , 26 , 39 52 week transplantation . Furthermore , patient follow prospectively time transplantation ten year regard cardiovascular event . Data concern cardiovascular event collect Norwegian renal registry whole study population follow period 10 year .</detailed_description>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Renal transplant recipient Adults , â‰¥ 18 year age Either gender Signed informed consent Persisting sCa &gt; 2.55 mmol/L ( first two week transplantation ) Impaired graft functioning ( estimate GFR &lt; 30 ml/min ) Previous ( within last 12 month ) treatment bisphosphonates , sodium fluoride , calcitonin , strontium , PTH , SERM , growth hormone anabolic steroid time transplantation . Known adynamic bone disease Previous parathyroidectomy Pregnant lactating female females childbearing potential use approve method contraception ( oral contraceptive IUD ) ; positive urine pregnancy test , applicable . Use investigational drug ( ) and/or device ( ) Previous participation trial History hypersensitivity bisphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Ibandronate</keyword>
	<keyword>Placebo</keyword>
	<keyword>Doubleblind</keyword>
	<keyword>Bone</keyword>
	<keyword>loss</keyword>
	<keyword>Kidney</keyword>
	<keyword>transplant</keyword>
</DOC>